Shares in AIM-listed drug firm 4D Pharma (LON:DDDD) dropped by 13.68% to 45.75p (as of 16:20 BST) after it reported a post-tax loss of £23.7 million for the year ended 31st December. Net assets dropped by more than 50% as the company ran clinical trials across a number of product lines.
Chairman Axel Glasmacher commented: “I am pleased to be able to announce the Group’s final results for the year ended 31 December 2019. 2019 was a successful year for the Group in which we made great progress in the clinic across multiple programmes, and entered collaborations with new partners. I would like to thank everyone in the Group for their valuable contributions as we look ahead to a pivotal year for 4D as we reach key readouts from multiple clinical studies“.